Immune checkpoint inhibitors (ICIs) are currently among the most widely used treatments for cancer. Chinese pharmaceutical companies have been making significant strides in developing PD-1 and PD-L1 inhibitors, used to treat various cancers. Several of these companies are now entering or planning to enter the US and European markets. Beigene, Hengrui Medicine, Junshi Biosciences, and Innovent Biologics are at the forefront of PD-1/PD-L1 development in China, with several approved and under-development assets.
One of the key motivators for Chinese PD-1 drug developers to expand internationally is the pricing pressure they face in their domestic market. Due to signif...
